Sacha Ninkovic
Overview
Explore the profile of Sacha Ninkovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freeman-Cook K, Hoffman R, Miller N, Almaden J, Chionis J, Zhang Q, et al.
Cancer Cell
. 2021 Sep;
39(10):1404-1421.e11.
PMID: 34520734
The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free survival in HR/HER2 breast cancer when combined with anti-hormonals. We sought to discover PAL resistance mechanisms in preclinical models and through analysis...
2.
Freeman-Cook K, Hoffman R, Behenna D, Boras B, Carelli J, Diehl W, et al.
J Med Chem
. 2021 Jun;
64(13):9056-9077.
PMID: 34110834
Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CDK...
3.
Bagal S, Andrews M, Bechle B, Bian J, Bilsland J, Blakemore D, et al.
J Med Chem
. 2018 Jun;
61(15):6779-6800.
PMID: 29944371
Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), are known to activate the family of Tropomyosin receptor...
4.
Kung P, Rui E, Bergqvist S, Bingham P, Braganza J, Collins M, et al.
J Med Chem
. 2016 Dec;
59(24):11196.
PMID: 27936698
No abstract available.
5.
Kung P, Rui E, Bergqvist S, Bingham P, Braganza J, Collins M, et al.
J Med Chem
. 2016 Aug;
59(18):8306-25.
PMID: 27512831
A new enhancer of zeste homolog 2 (EZH2) inhibitor series comprising a substituted phenyl ring joined to a dimethylpyridone moiety via an amide linkage has been designed. A preferential amide...
6.
Linton M, Burke B, Johnson T, Ninkovic S, Gajiwala K, Richardson P, et al.
Bioorg Med Chem
. 2015 May;
23(13):3408-13.
PMID: 25963824
Incorporation of nitrogen is a common medicinal chemistry tactic to reduce logD values. Neighboring group participation influences logD, so the results are isomer dependent. The logD and logP differences observed...
7.
Le P, Cheng H, Ninkovic S, Plewe M, Huang X, Wang H, et al.
Bioorg Med Chem Lett
. 2012 Jul;
22(15):5098-103.
PMID: 22749419
Lead optimization efforts that employed structure base drug design and physicochemical property based optimization leading to the discovery of a novel series of 4-methylpyrido pyrimidinone (MPP) are discussed. Synthesis and...
8.
Wang F, Ninkovic S, Collins M, Moore C, Rheingold A, Yanovsky A
Acta Crystallogr Sect E Struct Rep Online
. 2011 May;
66(Pt 8):o2021.
PMID: 21588332
The crystal structure of the title compound, C(5)H(3)BrN(2)S, shows that bromination of 1H-thieno[2,3-d]imidazole with N-bromo-succinimide in acetonitrile occurs at position 5 of the bicyclic system. The mol-ecule is almost planar,...
9.
Zehnder L, Bennett M, Meng J, Huang B, Ninkovic S, Wang F, et al.
J Med Chem
. 2011 Mar;
54(9):3368-85.
PMID: 21438541
A novel class of heat shock protein 90 (Hsp90) inhibitors was discovered by high-throughput screening and was subsequently optimized using a combination of structure-based design, parallel synthesis, and the application...
10.
Liu K, Bagrodia S, Bailey S, Cheng H, Chen H, Gao L, et al.
Bioorg Med Chem Lett
. 2010 Sep;
20(20):6096-9.
PMID: 20817449
Pteridinones were designed based on a non-selective kinase template. Because of the uniqueness of the PI3K and mTOR binding pockets, a methyl group was introduced to C-4 position of the...